IP Library Granted Patent US 8,962,691
Granted Patent B2
US 8,962,691 · App. 13/619,607 · Granted Feb 24, 2015

Retinoid replacements and opsin agonists and methods for the use thereof

Inventors: Krzysztof Palczewski (Bay Village, OH); David A. Saperstein (Seattle, WA)
Assignee: University of Washington
A61K31/07A61K38/1709A61K31/11A61K31/382A61K31/435A61K31/695Y10S514/912
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,691
App. No.
13/619,607
Granted
Feb 24, 2015
Kind
B2
Abstract

Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.

Claims (8)

1. A method of treating Leber Congenital Amaurosis (LCA) in an LRAT-defective human subject having a mutation in the gene encoding the LRAT protein, comprising:

administering a therapeutically effective amount of a 9-cis-retinal to the LRAT-defective human subject, wherein the LRAT-defective human subject has a deficiency of endogenous 11-cis-retinal in the eye and the 9-cis-retinal forms a functional opsin/chromophore complex in the eye.

2. The method of claim 1 , wherein the 9-cis-retinal is administered locally to the eye of the human subject.

3. The method of claim 2 , wherein the local administration is by eye drops, intraocular injection or periocular injection.

4. The method of claim 1 wherein the 9-cis-retinal is administered systemically by oral dosage form or injection.

5. A method of treating Leber Congenital Amaurosis (LCA) in an LRAT-defective human subject having a mutation in the gene encoding the LRAT protein, comprising:

administering a therapeutically effective amount of 9-cis-retinal by local administration to an eye of the LRAT-defective human subject, wherein the LRAT-defective human subject has a deficiency of endogenous 11-cis-retinal in the eye and the 9-cis-retinal forms a functional opsin/chromophore complex in the eye.

6. The method of claim 5 , wherein the local administration is by eye drops, intraocular injection or periocular injection.

Assignments (1)
CONFIRMATORY LICENSE Recorded Apr 18, 2013
From: UNIVERSITY OF WASHINGTON / CENTER FOR COMMERICALIZATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030241/0640 →
Continuity (4)
Continuation 13420465 · Mar 14, 2012
Continuation 10548612
Provisional Application 60455182 · Mar 14, 2003
Related Publication 20130072568A1 · Mar 21, 2013